Company Information
- Type:
- Company
- Country:
- United States of America
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Privately Held
- Global Compact Status:
- Active
- Participant Since
- 30 September 2010 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Communication On Progress
Published On | Title | Level/Status |
---|---|---|
01-Aug-2024 | 2024 Communication on Progress | Submitted |
21-Dec-2023 | 2023 Communication on Progress | Submitted |
26-Jul-2022 | 2022 Promega Corporate Responsibility Report | Active |
30-Jul-2021 | 2021 Promega Corporate Responsibility Report | Active |
05-Oct-2020 | 2020 Promega Corporate Responsibility Report | Active |
15-Jun-2019 | 2019 Promega Corporate Responsibility Report | Active |
15-Jun-2018 | 2018 Promega Corporate Responsibility Report | Active |
16-Jun-2017 | 2017 Promega Corporate Responsibility Report | Active |
17-Jun-2016 | 2016 Promega Corporate Responsibility Report | Active |
17-Jun-2015 | 2015 Promega Corporate Responsibility Report | Active |
17-Jun-2014 | 2013 Promega Corporate Responsibility Report | Active |
17-Jun-2013 | 2012 Promega Communication on Progress | Active |
10-Jul-2012 | 2011 Promega Corporate Responsibility Report | Active |
11-Jul-2011 | 2010 Corporate Responsibility Report | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.